Synaptogenix (SNPX) Stock Climbs Following Treasury Strategy Shift

Synaptogenix, Inc. (NASDAQ: SNPX) witnessed a remarkable upswing in its stock performance, with shares rising by 52.70% to $3.68 at last check. The surge follows the company’s announcement of a novel cryptocurrency-based treasury strategy. At the heart of this move is a targeted investment in TAO, the leading artificial intelligence (AI) cryptocurrency token by market capitalization and adoption.

Strategic Focus on TAO Token Acquisition

Synaptogenix plans an initial acquisition of $10 million worth of TAO tokens, a value exceeding twice the company’s current market capitalization. This bold strategy is a component of a larger plan to eventually amass up to $100 million in TAO tokens.

The initial funding will be sourced from the company’s robust cash reserves and well-capitalized balance sheet. The move reflects the board’s late-2024 strategic pivot to unlock shareholder value through digital asset integration—a trend increasingly seen across both public and private sectors.

Leadership and Industry Alignment

James Altucher, a well-known businessman and expert in AI and crypto, has been named to head Synaptogenix’s TAO-focused revenue plan. Altucher, an early advocate of Bitcoin and a published AI researcher, brings extensive experience in emerging technologies.

He will spearhead initiatives involving TAO staking and token appreciation, aiming to maximize returns for shareholders. TAO, the native currency of the decentralized Bittensor blockchain, is seen by Synaptogenix as a prime asset due to its fixed supply of 21 million tokens and rising demand driven by global AI adoption.

Corporate Rebranding and Financing Measures

Details of SNPX’s planned rebranding, which will include a new name, ticker symbol, and website, will be made public in the upcoming months in order to better match with its strategic goal.

A $5.5 million private placement financing deal including the issuing of Series D convertible preferred stock and warrants, both priced at $3.00 per share, was also disclosed by Synaptogenix (SNPX) at the same time. Under normal circumstances, the financing—in which Altucher is a participant—should close by June 10, 2025.